SOLIRIS (eculizumab): The first treatment specifically approved for PNH

Get Involved!

Across the US, you can find programs dedicated to bringing patients with PNH and their family and friends together. We have compiled a list of the upcoming events that may be of interest to you.

2008 Patient and Family Conference

Sponsored by the Aplastic Anemia & MDS International Foundation, Inc.
When: Sunday, July 27, 2008, through Wednesday, July 30, 2008
Where: Washington, DC For more information and to register, please visit: http://www.aamds.org/aplastic/information__hope/patient_and_family_c

Regional Patient Support Group Meeting

Sponsored by the National Organization for Rare Disorders
When: Saturday, August 2, 2008
Where: Denver, CO
Special Guest: Ilene Weitz, MD
Please RSVP by July 30, 2008, to Michele Counihan at 203.744.0100 x252

The 3rd Annual Walk for PNH

Sponsored by the PNH Foundation
When: Sunday, September 28, 2008
Where: Riverside Park, New York City
For more information, please visit: http://www.pnhfoundation.org/ 

 

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.

Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.